Is immunotherapy a viable option in treating mesothelioma?

References

• Lievense LA , StermanDH, CornelissenR, AertsJG. Checkpoint blockade in lung cancer and mesothelioma. Am. J. Respir. Crit. Care Med. doi:10.1164/rccm.201608-1755CI (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodríguez-AbreuD, RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ , RusthovenJJ, SymanowskiJet al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Zalcman G , MazieresJ, MargeryJet al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, Phase 3 trial. Lancet387(10026), 1405–1414 (2016).
   PubMed Web of Science ®Google Scholar
• Kim JM , ChenDS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.27(8), 1492–1504 (2016).
   PubMed Web of Science ®Google Scholar
• Bueno R , StawiskiEW, GoldsteinLDet al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet.48(4), 407–416 (2016).
   PubMed Web of Science ®Google Scholar
• Cornelissen R , LievenseLA, HeuversMEet al. Dendritic cell-based immunotherapy in mesothelioma. Immunotherapy4(10), 1011–1022 (2012).
   PubMed Web of Science ®Google Scholar
• Cornelissen R , HegmansJPJJ, MaatAPWMet al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med.193(9), 1023–1031 (2016).
   PubMed Web of Science ®Google Scholar
• Hegmans JP , VeltmanJD, LambersMEet al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am. J. Respir. Crit. Care Med.181(12), 1383–1390 (2010).
   PubMed Web of Science ®Google Scholar
• Aerts J , CornelissenR, LeestCVDet al. OA13.06 autologous dendritic cells loaded with allogeneic tumor cell lysate (Pheralys®) in patients with mesothelioma: final results of a Phase I study. J. Thorac. Oncol.12(1), S295 (2017).
   Web of Science ®Google Scholar
• Le DT , BrockstedtDG, Nir-PazRet al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.18(3), 858–868 (2012).
   PubMed Web of Science ®Google Scholar
• Motz GT , CoukosG. Deciphering and reversing tumor immune suppression. Immunity39(1), 61–73 (2013).
   PubMed Web of Science ®Google Scholar
• Marcq E , PauwelsP, van MeerbeeckJP, SmitsELJ. Targeting immune checkpoints: new opportunity for mesothelioma treatment?Cancer Treat. Rev.41(10), 914–924 (2015).
   PubMed Web of Science ®Google Scholar
• Kindler HL , ScherpereelA, CalabròLet al. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study. J. Clin. Oncol.34(Suppl. Abstract 8502), doi: 10.1200/JCO.2016.34.15_suppl.8502 (2016).
   Google Scholar
• Mayor M , ZeltsmanM, McGeeE, AdusumilliPS. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. Immunotherapy8(5), 491–494 (2016).
   PubMed Web of Science ®Google Scholar
• Yong CSM , DardalhonV, DevaudC, TaylorN, DarcyPK, KershawMH. CAR T-cell therapy of solid tumors. Immunol. Cell Biol.95(4), 356–363 (2017).
   PubMed Web of Science ®Google Scholar
• Marcq E , SiozopoulouV, De WaeleJet al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology6(1), e1261241 (2017).
   PubMed Web of Science ®Google Scholar
• Alley EW , LopezJ, SantoroAet al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, Phase 1b trial. Lancet Oncol.18(6), 623–630 (2017).
   PubMedGoogle Scholar
• Quispel-Janssen J , ZagoG, SchoutenRet al. OA13.01 A Phase II study of nivolu mab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopies. J. Thorac. Oncol.12(1), S292–S293 (2017).
   Google Scholar
• Hassan R , ThomasA, PatelMRet al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor Phase Ib trial: Safety, clinical activity, and PD-L1 expression. J. Clin. Oncol.34(Suppl. Abstract 8503), doi: 10.1200/JCO.2016.34.15_suppl.8503 (2016).
   PubMedGoogle Scholar
• Solinas G , GermanoG, MantovaniA, AllavenaP. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol.86(5), 1065–1073 (2009).
   PubMed Web of Science ®Google Scholar
• Lievense LA , BezemerK, AertsJG, HegmansJP. Tumor-associated macrophages in thoracic malignancies. Lung Cancer Amst. Neth.80(3), 256–262 (2013).
   PubMed Web of Science ®Google Scholar
• Dammeijer F , LievenseLA, AertsJGJVet al. Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol. Res.5(7), 535–546 (2017).
   PubMed Web of Science ®Google Scholar